Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

TIBSOVO (ivosidenib) for Relapsed or Refractory AML

TIBSOVO® is indicated for the treatment of relapsed or refractory acute myeloid leukaemia in patients with IDH1gene mutation. Image courtesy of Agios Inc.



  • TIBSOVO
  • TIBSOVO
  • TIBSOVO

Go Top